Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Fig. 2

Anti-PD-1/PD-L1 immunotherapy resistance caused by antigen recognition disorders. Loss of heterozygosity and frameshift mutations in beta-2-microglobulin (B2M) disrupt tumor antigen presentation, and PD-1-positive T cell infiltration is associated with B2M. MHCII promotes CD4+ T cell infiltration and expresses the inhibitory receptor LAG3, which limits antigen presentation and causes primary resistance to PD-1 blockade therapy

Back to article page

Molecular Cancer

ISSN: 1476-4598